Skip to content

Study · Randomized controlled trial · n = 17 · 2025

14 results

Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.

Guerdjikova AI, Blom TJ, Mori N, Romo-Nava F, McElroy SL

International journal of psychiatry in clinical practice24 Aug 2025

PMID40849800 (opens in a new tab)DOI10.1080/13651501.2025.2549307 (opens in a new tab)PepBankPUB-40849800
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    Among participants with binge eating disorder and stable bipolar disorder, liraglutide and placebo had similar reductions in percent change of body weight; this descriptive similarity does not establish statistical equivalence.

    In plain wordsIn overweight or obese participants with BED and stable bipolar disorder, liraglutide and placebo showed similar body-weight change reductions; significance was unspecified.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedpercent change in body weight
    Study

    n = 17

    Comparator
    placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among the 17 BED participants, liraglutide (N = 9) and placebo (n = 8) were associated with similar reductions in percent change of body weight and BES scores.
    2 context sentences
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight.
    Summary · context
    Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Among participants with binge eating disorder and stable bipolar disorder, liraglutide and placebo had similar reductions in Binge Eating Scale scores; this descriptive similarity does not establish statistical equivalence.

    In plain wordsIn overweight or obese participants with BED and stable bipolar disorder, liraglutide and placebo showed similar binge-eating scores reductions; significance was unspecified.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBinge Eating Scale score
    Study

    n = 17

    Comparator
    placebo
    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among the 17 BED participants, liraglutide (N = 9) and placebo (n = 8) were associated with similar reductions in percent change of body weight and BES scores.
    2 context sentences
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight.
    Summary · context
    Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    Among nine overweight/obese participants with BED and stable bipolar disorder receiving liraglutide, body weight decreased; placebo participants also showed reductions, and liraglutide did not show stated superiority.

    In plain wordsIn nine participants with BED, bipolar disorder and excess weight, weight decreased with liraglutide; placebo also improved, without stated superiority.

    Peptide
    Liraglutide
    Outcome
    Decreasebody weight reduction in the liraglutide-treated BED subset
    Study

    n = 9

    Comparator
    baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among the 17 BED participants, liraglutide (N = 9) and placebo (n = 8) were associated with similar reductions in percent change of body weight and BES scores.
    2 context sentences
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight.
    Summary · context
    Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    Among nine overweight/obese participants with BED and stable bipolar disorder receiving liraglutide, Binge Eating Scale score decreased; placebo participants also showed reductions, and liraglutide did not show stated superiority.

    In plain wordsIn nine participants with BED, bipolar disorder and excess weight, binge-eating scores decreased with liraglutide; placebo also improved, without stated superiority.

    Peptide
    Liraglutide
    Outcome
    DecreaseBinge Eating Scale score reduction in the liraglutide-treated BED subset
    Study

    n = 9

    Comparator
    baseline
    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among the 17 BED participants, liraglutide (N = 9) and placebo (n = 8) were associated with similar reductions in percent change of body weight and BES scores.
    2 context sentences
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight.
    Summary · context
    Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.
  5. 05HumanRandomized controlled trialSafety outcome

    In the trial of stable bipolar disorder with obesity or overweight, liraglutide was reported well tolerated; the actual native analysis N and a formal tolerability rate or comparison were unstated.

    In plain wordsIn overweight or obese participants with stable bipolar disorder, liraglutide was reportedly well tolerated; the exact rate and comparison were unspecified.

    Peptide
    Liraglutide
    Outcome
    Not applicableLiraglutide tolerability in bipolar-disorder weight-loss trial
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (p = .04), constipation (p = .02) and anxiety (p = .02).
    2 context sentences
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight.
    Summary · context
    Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 06HumanNot a test of Liraglutide aloneObservational studyOther

    Among trial participants with stable bipolar disorder and obesity or overweight, those with binge eating disorder had higher body mass index than those without binge eating disorder.

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had higher BMI than participants without BED.

    Peptide
    Liraglutide
    Outcome
    Increasebody mass index
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and h…
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 07HumanNot a test of Liraglutide aloneObservational studyOther

    Among trial participants with stable bipolar disorder and obesity or overweight, those with binge eating disorder had higher HbA1c levels than those without binge eating disorder.

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had higher HbA1c than participants without BED.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and h…
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 08HumanNot a test of Liraglutide aloneObservational studyOther

    Among trial participants with stable bipolar disorder and obesity or overweight, those with binge eating disorder were taking more antidepressants than those without binge eating disorder.

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had more antidepressant use than participants without BED.

    Peptide
    Liraglutide
    Outcome
    Increaseantidepressant use
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Patterns of use · Pharmacology

    Source sentences

    Summary
    Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and h…
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 09HumanNot a test of Liraglutide aloneObservational studyOther

    Among trial participants with stable bipolar disorder and obesity or overweight, those with binge eating disorder had higher Binge Eating Scale scores than those without binge eating disorder.

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had higher binge-eating scores than participants without BED.

    Peptide
    Liraglutide
    Outcome
    IncreaseBinge Eating Scale score
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Appetite and food intake · Mental health and mood

    Source sentences

    Summary
    Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and h…
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 10HumanNot a test of Liraglutide aloneObservational studyOther

    Among trial participants with stable bipolar disorder and obesity or overweight, those with binge eating disorder had higher Three Factor Eating Questionnaire disinhibition scores than those without binge eating disorder.

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had higher eating-disinhibition scores than participants without BED.

    Peptide
    Liraglutide
    Outcome
    IncreaseThree Factor Eating Questionnaire disinhibition score
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Appetite and food intake · Mental health and mood

    Source sentences

    Summary
    Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and h…
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 11HumanNot a test of Liraglutide aloneObservational studyOther

    Among trial participants with stable bipolar disorder and obesity or overweight, those with binge eating disorder had higher Three Factor Eating Questionnaire hunger scores than those without binge eating disorder.

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had higher hunger scores than participants without BED.

    Peptide
    Liraglutide
    Outcome
    IncreaseThree Factor Eating Questionnaire hunger score
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Appetite and food intake · Mental health and mood

    Source sentences

    Summary
    Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and h…
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 12HumanNot a test of Liraglutide aloneObservational studySafety outcome

    Among trial participants, the binge eating disorder group experienced more nausea/vomiting than those without binge eating disorder (p = .04).

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had more nausea or vomiting than participants without BED.

    Peptide
    Liraglutide
    Outcome
    Increasenausea/vomiting
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (p = .04), constipation (p = .02) and anxiety (p = .02).
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 13HumanNot a test of Liraglutide aloneObservational studySafety outcome

    Among trial participants, the binge eating disorder group experienced more constipation than those without binge eating disorder (p = .02).

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had more constipation than participants without BED.

    Peptide
    Liraglutide
    Outcome
    Increaseconstipation
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (p = .04), constipation (p = .02) and anxiety (p = .02).
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  9. 14HumanNot a test of Liraglutide aloneObservational studySafety outcome

    Among trial participants, the binge eating disorder group experienced more anxiety than those without binge eating disorder (p = .02).

    In plain wordsIn overweight or obese participants with stable bipolar disorder, those with BED had more anxiety than participants without BED.

    Peptide
    Liraglutide
    Outcome
    Increaseanxiety
    Study

    n = 60

    Comparator
    participants without binge eating disorder
    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (p = .04), constipation (p = .02) and anxiety (p = .02).
    1 context sentence
    Summary · context
    This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment,…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.